0 CHECKOUT

PRODUCT FILTERS

REGION

1,006
90
64
61
53

COUNTRY

58
13
11
8
6

CATEGORIES

  • 73
  • 124
  • 60
  • 54
  • 35
  • 33
  • 10
  • 10
  • 11
  • 14

PRICE

543
799
1,663
2,767

PUBLISHED

59
237
601
2,767

PRODUCT TYPE

2,663
84
7
6
2
2
2
1

Oncology

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

2,767 Products

Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2014

Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2014 Summary This, ‘Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2014’, provides an overview of the Glioblastoma Multiforme (GBM)’s therapeutic...

Published:  September 2014
Price:  From

PharmaPoint: HER2-Positive Breast Cancer - Japan Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - Japan Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer...

Published:  September 2014
Price:  From

PharmaPoint: HER2-Positive Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer...

Published:  September 2014
Price:  From

Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Kadcyla (HER2-Positive Breast Cancer) -...

Published:  September 2014
Price:  From

PharmaPoint: HER2-Positive Breast Cancer - China Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - China Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer...

Published:  September 2014
Price:  From

PharmaPoint: HER2-Positive Breast Cancer - US Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - US Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer...

Published:  September 2014
Price:  From

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer...

Published:  September 2014
Price:  From

Waldenstrom Macroglobulinemia - Pipeline Review, H2 2014

Waldenstrom Macroglobulinemia - Pipeline Review, H2 2014 Summary This, ‘Waldenstrom Macroglobulinemia - Pipeline Review, H2 2014’, provides an overview of the Waldenstrom Macroglobulinemia’s therapeutic...

Published:  September 2014
Price:  From

Hairy Cell Leukemia - Pipeline Review, H2 2014

Hairy Cell Leukemia - Pipeline Review, H2 2014 Summary This, ‘Hairy Cell Leukemia - Pipeline Review, H2 2014’, provides an overview of the Hairy Cell Leukemia’s therapeutic pipeline. This report...

Published:  September 2014
Price:  From

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014 Summary This, ‘Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014’, provides an overview of the Refractory...

Published:  September 2014
Price:  From

Metastatic Ovarian Cancer - Pipeline Review, H2 2014

Metastatic Ovarian Cancer - Pipeline Review, H2 2014 Summary This, ‘Metastatic Ovarian Cancer - Pipeline Review, H2 2014’, provides an overview of the Metastatic Ovarian Cancer’s therapeutic pipeline. This...

Published:  September 2014
Price:  From

Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014

Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014 Summary This, ‘Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014’, provides an overview...

Published:  September 2014
Price:  From

Asia-Pacific Nuclear Medicine Market – Trends And Forecasts (2014-2020)

Asia-pacific nuclear medicine market was valued at $480.5 million in 2012 and is expected to reach $853 million in 2019 with a healthy CAGR of 10.6%. One of the popular forms of medical specialty,...

Published:  September 2014
Price:  From

North America Nuclear Medicine Market – Trends And Forecasts (2014-2020)

North America market for nuclear medicine was valued to be $1.8 billion in 2014, and is poised to reach $2.5 billion in 2019 with a CAGR of 7.68%. Market is mostly driven by the therapeutic radiopharmaceutical...

Published:  September 2014
Price:  From

Asia-Pacific Clinical Data Analytics In Healthcare – Growth, Trends And Forecasts (2014 – 2019)

Big Data is the new buzzword in Healthcare industry. Experts are now realizing its benefits and adopting different solutions as per the requirements. One such solution which is seeing a high adoption...

Published:  September 2014
Price:  From

Anaplastic Thyroid Cancer - Pipeline Review, H2 2014

Anaplastic Thyroid Cancer - Pipeline Review, H2 2014 Summary This, ‘Anaplastic Thyroid Cancer - Pipeline Review, H2 2014’, provides an overview of the Anaplastic Thyroid Cancer’s therapeutic pipeline. This...

Published:  September 2014
Price:  From

Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting

This report provides in-depth insights into the indication. It gives an estimation of market size for 2013 along with forecasts until 2020 for the Asia-Pacific (APAC) region, which comprises Australia,...

Published:  September 2014
Price:  From

Europe Nuclear Medicine Market – Trends And Forecasts (2014-2020)

Europe market for nuclear medicine stood at $1.4 billion in 2014 and is expected to reach approximately $1.9 billion in 2019 with a CAGR of 7.2%. Market for Technetium-99m is expected to increase owing...

Published:  September 2014
Price:  From

Uterine Cancer - Pipeline Review, H2 2014

Uterine Cancer - Pipeline Review, H2 2014 Summary This, ‘Uterine Cancer - Pipeline Review, H2 2014’, provides an overview of the Uterine Cancer’s therapeutic pipeline. This report provides comprehensive...

Published:  September 2014
Price:  From

Burkitt Lymphoma - Pipeline Review, H2 2014

Burkitt Lymphoma - Pipeline Review, H2 2014 Summary This, ‘Burkitt Lymphoma - Pipeline Review, H2 2014’, provides an overview of the Burkitt Lymphoma’s therapeutic pipeline. This report provides...

Published:  September 2014
Price:  From
Loading Indicator

Our Clients